Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Railroads | 1 | 2021 | 76 | 0.84 | Why? |
| Tuberculosis, Pulmonary | 5 | 2018 | 1171 | 0.59 | Why? |
| Bayes Theorem | 2 | 2021 | 3237 | 0.45 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.41 | Why? |
| Social Determinants of Health | 1 | 2021 | 1757 | 0.38 | Why? |
| Computational Biology | 2 | 2021 | 4514 | 0.32 | Why? |
| Models, Statistical | 4 | 2021 | 5312 | 0.31 | Why? |
| Databases, Factual | 1 | 2021 | 6248 | 0.31 | Why? |
| Tuberculin Test | 4 | 2018 | 141 | 0.28 | Why? |
| Mycobacterium tuberculosis | 5 | 2018 | 1164 | 0.25 | Why? |
| Tuberculosis, Multidrug-Resistant | 2 | 2018 | 433 | 0.24 | Why? |
| Tuberculosis | 4 | 2021 | 2895 | 0.24 | Why? |
| Population Surveillance | 1 | 2016 | 4967 | 0.19 | Why? |
| Benzoxazines | 1 | 2019 | 103 | 0.19 | Why? |
| Ozone | 2 | 2017 | 757 | 0.19 | Why? |
| Rifampin | 2 | 2018 | 276 | 0.18 | Why? |
| Boston | 5 | 2021 | 929 | 0.18 | Why? |
| Safety-net Providers | 1 | 2020 | 302 | 0.17 | Why? |
| HIV Integrase Inhibitors | 1 | 2019 | 173 | 0.17 | Why? |
| Tobacco Products | 1 | 2021 | 245 | 0.17 | Why? |
| Nitrogen Dioxide | 2 | 2017 | 488 | 0.17 | Why? |
| Dengue Vaccines | 1 | 2018 | 123 | 0.16 | Why? |
| Parasitic Diseases | 1 | 2017 | 84 | 0.15 | Why? |
| Biostatistics | 1 | 2017 | 116 | 0.15 | Why? |
| South Africa | 4 | 2021 | 3326 | 0.15 | Why? |
| Meditation | 1 | 2017 | 140 | 0.14 | Why? |
| Antitubercular Agents | 2 | 2018 | 775 | 0.14 | Why? |
| Vaccines, Virus-Like Particle | 1 | 2018 | 312 | 0.14 | Why? |
| Basic Reproduction Number | 3 | 2021 | 2676 | 0.14 | Why? |
| Computer Simulation | 2 | 2021 | 4982 | 0.13 | Why? |
| Behavior Therapy | 1 | 2017 | 235 | 0.13 | Why? |
| Hospital Units | 1 | 2021 | 1017 | 0.13 | Why? |
| Central Nervous System | 1 | 2019 | 701 | 0.13 | Why? |
| Probability | 1 | 2017 | 923 | 0.12 | Why? |
| Latent Tuberculosis | 1 | 2017 | 324 | 0.12 | Why? |
| Inhalation Exposure | 1 | 2017 | 405 | 0.12 | Why? |
| Family Characteristics | 3 | 2018 | 2551 | 0.12 | Why? |
| African Americans | 2 | 2017 | 3363 | 0.11 | Why? |
| Mindfulness | 1 | 2017 | 437 | 0.11 | Why? |
| Drug Resistance, Bacterial | 2 | 2018 | 1414 | 0.11 | Why? |
| Urban Population | 1 | 2021 | 2000 | 0.11 | Why? |
| Dengue Virus | 1 | 2018 | 910 | 0.10 | Why? |
| Housing | 1 | 2018 | 1146 | 0.10 | Why? |
| Long QT Syndrome | 1 | 2020 | 1047 | 0.10 | Why? |
| Homeless Persons | 1 | 2021 | 1171 | 0.10 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.10 | Why? |
| Contact Tracing | 3 | 2021 | 8448 | 0.10 | Why? |
| Disease Outbreaks | 2 | 2017 | 27595 | 0.09 | Why? |
| Ambulances | 1 | 2011 | 287 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.09 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.09 | Why? |
| Brazil | 4 | 2018 | 12582 | 0.09 | Why? |
| Cough | 2 | 2018 | 4891 | 0.08 | Why? |
| Isoniazid | 2 | 2018 | 105 | 0.08 | Why? |
| New York City | 1 | 2021 | 7432 | 0.08 | Why? |
| Patient Isolation | 1 | 2021 | 3182 | 0.08 | Why? |
| Refugees | 1 | 2017 | 809 | 0.08 | Why? |
| Poverty | 1 | 2019 | 2302 | 0.08 | Why? |
| Anti-HIV Agents | 1 | 2019 | 2209 | 0.08 | Why? |
| Alcohol Drinking | 1 | 2018 | 1663 | 0.08 | Why? |
| Environmental Exposure | 1 | 2017 | 1558 | 0.08 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.08 | Why? |
| Electrocardiography | 1 | 2020 | 3957 | 0.08 | Why? |
| Universities | 1 | 2021 | 4374 | 0.08 | Why? |
| Viral Envelope Proteins | 1 | 2018 | 3539 | 0.07 | Why? |
| Dengue | 1 | 2018 | 1565 | 0.07 | Why? |
| Interferon-gamma Release Tests | 2 | 2018 | 253 | 0.07 | Why? |
| Humans | 32 | 2021 | 930598 | 0.07 | Why? |
| Long-Term Care | 1 | 2017 | 2047 | 0.07 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.07 | Why? |
| Particulate Matter | 1 | 2017 | 3249 | 0.07 | Why? |
| Patient Selection | 1 | 2019 | 4560 | 0.07 | Why? |
| Life Style | 1 | 2017 | 2708 | 0.07 | Why? |
| Algorithms | 1 | 2021 | 7346 | 0.07 | Why? |
| Patient Transfer | 1 | 2011 | 898 | 0.07 | Why? |
| Female | 21 | 2021 | 380317 | 0.07 | Why? |
| Socioeconomic Factors | 1 | 2021 | 8495 | 0.06 | Why? |
| Adult | 17 | 2021 | 244371 | 0.06 | Why? |
| Young Adult | 10 | 2021 | 93724 | 0.06 | Why? |
| Japan | 1 | 2016 | 6653 | 0.06 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.06 | Why? |
| Male | 18 | 2021 | 367725 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 2984 | 0.06 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.06 | Why? |
| Antigens, Viral | 1 | 2018 | 6298 | 0.05 | Why? |
| Proportional Hazards Models | 3 | 2018 | 6543 | 0.05 | Why? |
| Alkynes | 1 | 2019 | 98 | 0.05 | Why? |
| gamma-Aminobutyric Acid | 1 | 2019 | 52 | 0.05 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.05 | Why? |
| Glutamic Acid | 1 | 2019 | 65 | 0.05 | Why? |
| Glycerophospholipids | 1 | 2018 | 12 | 0.05 | Why? |
| Glutamine | 1 | 2019 | 111 | 0.05 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.05 | Why? |
| Sputum | 2 | 2018 | 1720 | 0.05 | Why? |
| Culture Techniques | 1 | 2018 | 36 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.05 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.05 | Why? |
| Air Pollutants | 1 | 2017 | 3110 | 0.05 | Why? |
| Aged | 11 | 2021 | 215776 | 0.05 | Why? |
| Communication | 1 | 2017 | 5206 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.05 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.05 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 229 | 0.04 | Why? |
| Air Pollution | 1 | 2017 | 3504 | 0.04 | Why? |
| Ethionamide | 1 | 2017 | 5 | 0.04 | Why? |
| Masks | 1 | 2021 | 8528 | 0.04 | Why? |
| Tobacco Use | 1 | 2021 | 340 | 0.04 | Why? |
| Integrative Medicine | 1 | 2019 | 97 | 0.04 | Why? |
| Half-Life | 1 | 2018 | 298 | 0.04 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.04 | Why? |
| Glutathione | 1 | 2019 | 280 | 0.04 | Why? |
| Interrupted Time Series Analysis | 1 | 2021 | 868 | 0.04 | Why? |
| Group Processes | 1 | 2019 | 210 | 0.04 | Why? |
| Cyclopropanes | 1 | 2019 | 332 | 0.04 | Why? |
| Neuropsychology | 1 | 2019 | 198 | 0.04 | Why? |
| Infant | 2 | 2017 | 30274 | 0.04 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.04 | Why? |
| Random Allocation | 1 | 2019 | 773 | 0.04 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Ethanol | 1 | 2021 | 533 | 0.04 | Why? |
| Child, Preschool | 2 | 2017 | 36283 | 0.04 | Why? |
| Population Density | 1 | 2021 | 694 | 0.04 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.04 | Why? |
| Infectious Disease Medicine | 1 | 2018 | 311 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2019 | 88759 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.03 | Why? |
| Massachusetts | 1 | 2019 | 1279 | 0.03 | Why? |
| Geographic Information Systems | 1 | 2018 | 507 | 0.03 | Why? |
| Stress, Psychological | 1 | 2017 | 10231 | 0.03 | Why? |
| Immunity, Herd | 1 | 2021 | 1011 | 0.03 | Why? |
| Disease Transmission, Infectious | 1 | 2016 | 9044 | 0.03 | Why? |
| Child | 3 | 2017 | 70012 | 0.03 | Why? |
| Neurons | 1 | 2019 | 864 | 0.03 | Why? |
| Blood Cell Count | 1 | 2018 | 1101 | 0.03 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2018 | 1182 | 0.03 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.03 | Why? |
| United States | 4 | 2021 | 46150 | 0.03 | Why? |
| Influenza, Human | 1 | 2016 | 10779 | 0.03 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.03 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Hand Hygiene | 1 | 2021 | 1493 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Chronic Pain | 1 | 2019 | 736 | 0.03 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.02 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.02 | Why? |
| Oxidative Stress | 1 | 2019 | 2050 | 0.02 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.02 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.02 | Why? |
| Reagent Kits, Diagnostic | 1 | 2017 | 2149 | 0.02 | Why? |
| Substance-Related Disorders | 1 | 2021 | 2038 | 0.02 | Why? |
| Communicable Disease Control | 3 | 2021 | 29620 | 0.02 | Why? |
| Emergency Service, Hospital | 1 | 2011 | 14232 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Logistic Models | 1 | 2020 | 9089 | 0.02 | Why? |
| Epitopes | 1 | 2018 | 4113 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.02 | Why? |
| Feeding Behavior | 1 | 2017 | 1909 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.02 | Why? |
| Vulnerable Populations | 1 | 2019 | 3099 | 0.02 | Why? |
| Neutralization Tests | 1 | 2018 | 6698 | 0.02 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Feces | 1 | 2017 | 4235 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.02 | Why? |
| Hospitals, Teaching | 1 | 2011 | 1609 | 0.02 | Why? |
| Disease Management | 1 | 2021 | 6841 | 0.02 | Why? |
| Referral and Consultation | 1 | 2019 | 4816 | 0.02 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.01 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
| Aerosols | 1 | 2018 | 5393 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Vero Cells | 1 | 2018 | 14117 | 0.01 | Why? |
| Molecular Diagnostic Techniques | 1 | 2017 | 4239 | 0.01 | Why? |
| Time Factors | 2 | 2017 | 31397 | 0.01 | Why? |
| Nursing Homes | 1 | 2017 | 4155 | 0.01 | Why? |
| India | 1 | 2017 | 11875 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Inflammation | 1 | 2019 | 13255 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.01 | Why? |
| Patient Admission | 1 | 2011 | 5250 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.01 | Why? |
| HIV Infections | 1 | 2019 | 11620 | 0.01 | Why? |
| Length of Stay | 1 | 2011 | 11042 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2018 | 25288 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
White's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(216)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(124)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_